Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Monopar TherapeuticsMNPR -5.35%33 3-1 Month Momentum % is 77.55% as of Aug. 01, 2026. GuruFocus rates MNPR with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 1,389 Biotechnology companies, Monopar Therapeutics ranks better than 96.98% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-01), Monopar Therapeutics's 3-1 Month Momentum % is 77.55%.
The industry rank for Monopar Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
MNPR's 3-1 Month Momentum % is ranked better than 96.98% of 1389
companies
in the Biotechnology industry
Industry Median: -7.65
vs MNPR: 77.55
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Monopar Therapeutics 3-1 Month Momentum % Related Terms
MNPR vs DSGN, CLYM, ACRS: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Monopar Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monopar Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Monopar Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Monopar Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monopar Therapeutics (MNPR) has a 3-1 Month Momentum % of 77.55% as of Aug. 01, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Monopar Therapeutics and its competitors. According to the industry distribution chart, Monopar Therapeutics ranks #42 out of 1389 companies in the Biotechnology industry, placing it in the top 3%.
Is Monopar Therapeutics' 3-1 Month Momentum % too high?
Monopar Therapeutics' current 3-1 Month Momentum % is 77.55%. Based on the distribution chart, Monopar Therapeutics ranks #42 out of 1389 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Monopar Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Monopar Therapeutics' 3-1 Month Momentum % compare to DSGN and CLYM?
According to the Biotechnology industry distribution chart, Monopar Therapeutics ranks #42 out of 1389 companies for 3-1 Month Momentum %. This places Monopar Therapeutics in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Monopar Therapeutics and its competitors. Monopar Therapeutics's current 3-1 Month Momentum % is 77.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monopar Therapeutics stock overvalued right now?
Monopar Therapeutics (MNPR) has a current 3-1 Month Momentum % of 77.55%. The current 3-1 Month Momentum % is 77.55%. Monopar Therapeutics' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Monopar Therapeutics (MNPR), the current 3-1 Month Momentum % is 77.55% as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
33GF Score
Get the complete analysis for MNPR
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNPR has been successfully added to your 
